Last updated: August 5, 2026
Pepcid, the consumer brand for famotidine, is a mature acid-reducing franchise with low patent risk and durable retail demand. Its commercial value comes from brand recognition, OTC distribution, product extensions, and the shift away from ranitidine after its 2020 market withdrawal. Kenvue owns the principal U.S. consumer-health platform for Pepcid following the separation of Johnson & Johnson’s consumer-health business. Pepcid revenue is not publicly reported as a standalone line item, so financial analysis must rely on Kenvue’s broader Self Care segment and market-level indicators.
What is Pepcid and who owns the brand?
Pepcid contains famotidine, an H2-receptor antagonist that reduces gastric acid secretion. The brand is sold in prescription and OTC forms, although the commercial center of gravity is now OTC.
| Product or market |
Active ingredient |
Primary use |
Commercial status |
| Pepcid AC |
Famotidine |
Heartburn relief and acid reduction |
OTC |
| Pepcid Maximum Strength |
Famotidine, commonly 20 mg |
Frequent heartburn |
OTC |
| Pepcid Complete |
Famotidine plus antacid ingredients |
Rapid and longer-duration heartburn relief |
OTC combination |
| Generic famotidine tablets |
Famotidine |
Prescription and OTC acid reduction |
Generic |
| Prescription Pepcid |
Famotidine |
GERD, ulcers, hypersecretory conditions |
Genericized prescription market |
Kenvue markets Pepcid in the United States as part of its Self Care portfolio. Kenvue was separated from Johnson & Johnson in 2023 and owns or commercializes brands that include Tylenol, Motrin, Zyrtec, Benadryl, Nicorette, and Pepcid (Kenvue, 2024a).
Merck originally developed and commercialized Pepcid. The brand moved through the Johnson & Johnson consumer-health portfolio before becoming part of Kenvue’s publicly traded consumer-health business.
How large is the Pepcid market?
Pepcid competes in the U.S. heartburn and acid-reducer market, which includes H2 blockers, proton-pump inhibitors, antacids, alginates, and combination products. The addressable market is substantially larger than the narrow famotidine category because consumers often switch among product classes based on symptom frequency, speed of relief, and physician recommendations.
The principal competitive products are:
- Prilosec OTC, omeprazole, owned by Procter & Gamble in the United States.
- Nexium 24HR, esomeprazole, associated with Haleon.
- Prevacid 24HR, lansoprazole, associated with Bayer.
- Tums and Rolaids, calcium carbonate and related antacid products.
- Generic famotidine sold by multiple manufacturers.
- Store-brand H2 blockers and proton-pump inhibitors.
Pepcid has several commercial advantages:
- Famotidine has a rapid onset relative to proton-pump inhibitors.
- The product is associated with an established prescription history.
- Pepcid Complete combines H2 blockade with immediate antacid action.
- The brand benefited from consumer substitution after the withdrawal of ranitidine.
- H2 blockers remain attractive for intermittent, rather than continuous, symptoms.
Its limitations are equally clear. Generic famotidine is widely available, proton-pump inhibitors have stronger positioning for frequent acid suppression, and private-label products exert price pressure in mass retail, pharmacy, club, and e-commerce channels.
What is Pepcid’s financial trajectory?
Pepcid’s standalone revenue is not disclosed by Kenvue. The company reports financial results by operating segment and geographic region rather than by individual consumer brand. The relevant financial indicator is Kenvue’s Self Care segment, which includes multiple large brands and does not permit a precise Pepcid revenue calculation (Kenvue, 2024a; Kenvue, 2024b).
Kenvue reported approximately $15.4 billion in total 2023 sales. Self Care was one of the company’s principal operating segments. Pepcid contributed to the segment, but Kenvue did not identify its revenue, gross margin, or volume separately.
Revenue trajectory by market phase
| Period |
Market event |
Likely effect on Pepcid |
| Before 2019 |
Mature OTC heartburn category |
Stable, brand-led demand |
| 2019-2020 |
Ranitidine recalls and withdrawal |
Significant substitution benefit |
| 2021 |
Post-withdrawal normalization |
Elevated demand began to moderate |
| 2022-2024 |
Inflation, retailer inventory controls, and private-label competition |
Pricing support but pressure on unit volume |
| 2024 onward |
Mature category with product innovation |
Incremental growth from combinations, dosage formats, and retail execution |
The 2020 removal of ranitidine products created a major demand transfer to famotidine and other acid reducers. FDA testing identified unacceptable levels of N-nitrosodimethylamine, or NDMA, in ranitidine products under certain storage conditions. FDA requested that all ranitidine products be withdrawn from the U.S. market in April 2020 (FDA, 2020).
Pepcid was one of the most visible beneficiaries of that transition. The benefit was strongest during the acute substitution period. The long-term trajectory is more likely to be characterized by stable or modest growth than by a repeat of the 2020 surge.
Financial quality of the franchise
Pepcid has the economics of a mature OTC brand:
- Low development expense because the active ingredient is long established.
- Limited patent-related cash outlays.
- High gross-margin potential for branded products.
- Meaningful trade-spend and retailer-promotion requirements.
- Exposure to generic and private-label substitution.
- Sales sensitivity to shelf placement, search visibility, and seasonal demand.
The brand’s financial value is therefore based on marketing efficiency and distribution rather than exclusivity. Product extensions such as Pepcid Complete can support higher realized pricing than basic famotidine tablets because the consumer is purchasing a differentiated delivery concept rather than only the molecule.
When did Pepcid lose patent exclusivity?
Pepcid’s core small-molecule exclusivity expired decades ago. Famotidine is not protected today by a commercially meaningful composition-of-matter patent barrier in the United States.
The original famotidine patent was U.S. Patent No. 4,496,737, assigned to Merck-related interests and directed to famotidine compounds and pharmaceutical compositions. The patent was granted in 1985 and reached the end of its U.S. term in the early 2000s under the pre-Hatch-Waxman patent-term framework.
| IP category |
Status |
| Famotidine composition of matter |
Expired |
| Original Pepcid formulation protection |
Expired or commercially immaterial |
| Prescription famotidine exclusivity |
Expired |
| OTC brand protection |
Trademark and trade dress remain relevant |
| Current patent barrier to generic famotidine |
None of practical significance |
Pepcid’s remaining legal protection is primarily trademark, packaging, trade dress, regulatory compliance, and commercial execution. Those protections do not prevent competitors from selling famotidine under different names.
What patents protect Pepcid today?
No active patent estate appears to provide a material barrier to generic famotidine or competing OTC acid reducers. Any later patents covering specific formulations, packaging systems, dosing regimens, or combinations would need to be evaluated individually, but they would not restore broad exclusivity over famotidine.
The relevant protection layers are:
Trademark protection
The PEPCID mark and related product names can restrict confusingly similar branding. Trademark rights support premium pricing and shelf recognition but do not block generic famotidine.
Formulation protection
Pepcid Complete combines famotidine with antacid ingredients. A combination product can have formulation or regulatory distinctions, but competitors can develop alternative combinations without infringing the expired famotidine compound patent if their formulation claims are designed independently.
Method-of-use protection
Historically, famotidine patents and regulatory labeling covered indications such as GERD, peptic ulcer disease, and pathological hypersecretory conditions. Those use rights are no longer a meaningful barrier because the central indications are long established and generic competitors have entered.
Manufacturing and supply-chain protection
Manufacturing know-how can affect cost, quality, and supply reliability. It is not a substitute for an enforceable composition-of-matter patent. Famotidine is a conventional small molecule with multiple potential sources of active pharmaceutical ingredient and finished-dose manufacturing capacity.
What is the FDA regulatory and Orange Book status of Pepcid?
Pepcid OTC products are regulated through FDA OTC requirements, labeling rules, and applicable monograph conditions. The core product is not dependent on current prescription-drug exclusivity.
The Orange Book primarily identifies approved prescription drug products and patents or exclusivity associated with those products. OTC Pepcid products generally are not protected through an Orange Book-listed patent strategy comparable to a recently approved prescription drug (FDA, 2024a).
Prescription regulatory history
Famotidine received FDA approval as a prescription acid-reducing drug before generic competition developed. Generic famotidine products are approved through abbreviated new drug applications, or ANDAs, and are therapeutically equivalent when assigned the applicable FDA rating.
OTC status
OTC famotidine products are marketed under the FDA’s nonprescription drug framework. Labeling must comply with permitted indications, dosage instructions, warnings, and active-ingredient requirements. Pepcid’s commercial positioning depends on compliant OTC labeling rather than a period of newly granted prescription exclusivity.
Are there Paragraph IV challenges to Pepcid?
Paragraph IV litigation is not a central risk for current OTC Pepcid sales. The main reason is that famotidine generic entry occurred long ago, and the original patent estate has expired.
Paragraph IV certifications are relevant when an ANDA applicant challenges a listed patent for a prescription reference product. For a mature molecule such as famotidine, the commercial dispute is generally no longer whether a generic may enter. The issue is price, manufacturing cost, channel access, and brand substitution.
No current, material Paragraph IV dispute is necessary to explain Pepcid’s market position. The generic market is established, and Pepcid competes as a branded OTC product.
What litigation and settlement agreements affect Pepcid?
Pepcid does not have a current litigation profile comparable to patented blockbuster drugs facing repeated ANDA challenges. The most important legal events affecting the franchise have involved:
- Historical patent expiration and generic entry.
- Product liability and consumer litigation risks common to OTC medicines.
- Regulatory compliance and labeling.
- Supply, manufacturing, and advertising disputes.
- Brand protection and trademark enforcement.
No settlement agreement is required to explain current generic access to famotidine. Generic availability follows the expiration of the foundational patent and the approval of competing products, rather than a continuing branded-generic settlement structure.
How strong is the Pepcid patent estate?
Pepcid’s patent estate is weak as an exclusivity asset but strong as a mature commercial platform.
| Dimension |
Assessment |
| Composition-of-matter protection |
Very weak; expired |
| Formulation exclusivity |
Limited and product-specific |
| Method-of-use protection |
Expired or commercially limited |
| Trademark protection |
Meaningful |
| Regulatory complexity |
Low to moderate |
| Manufacturing barriers |
Low to moderate |
| Brand recognition |
Strong |
| Generic substitution risk |
High |
| Litigation leverage |
Low |
| Cash-flow durability |
Moderate |
The central distinction is between patent strength and brand strength. Pepcid has little ability to prevent competition, but it can retain consumer demand through familiarity, physician recognition, retail availability, and product differentiation.
What generic entry risks exist for Pepcid?
Generic and private-label competition is the main structural risk. Retailers can place store-brand famotidine next to Pepcid at materially lower prices. Pharmacy benefit managers and consumers can also substitute generic prescription famotidine when a clinician prescribes the molecule.
The most important risks are:
- Retail price compression.
- Loss of shelf space to private-label products.
- Reduced promotional efficiency as the category matures.
- Consumer migration to proton-pump inhibitors.
- Retailer concentration and bargaining power.
- Shortages or quality events affecting third-party manufacturers.
- Lower demand after the ranitidine substitution effect fades.
Pepcid can offset part of this pressure through combination products, convenience formats, strong packaging, and consumer advertising. Those measures support share but do not eliminate molecule-level substitution.
Which companies compete with Pepcid?
Pepcid competes against branded and generic manufacturers across multiple therapeutic classes.
| Competitor |
Molecule or category |
Competitive basis |
| Generic famotidine manufacturers |
Famotidine |
Lowest price and pharmacy access |
| Store brands |
Famotidine, omeprazole, antacids |
Retailer control and price |
| Prilosec OTC |
Omeprazole |
Strong PPI brand and frequent-heartburn positioning |
| Nexium 24HR |
Esomeprazole |
PPI efficacy positioning |
| Prevacid 24HR |
Lansoprazole |
Established PPI brand |
| Tums and Rolaids |
Antacids |
Fast symptomatic relief |
| Gaviscon |
Alginate and antacid formulations |
Barrier-forming and reflux positioning |
Pepcid is differentiated by its middle position between rapid but short-acting antacids and slower, longer-acting proton-pump inhibitors.
What licensing deals support Pepcid?
Pepcid’s current commercial position does not depend on a major recently announced licensing transaction. The brand’s ownership history reflects corporate portfolio transfers, including the movement of Johnson & Johnson’s consumer-health assets into Kenvue.
The relevant commercial relationship is Kenvue’s ownership and marketing of the consumer-health brand portfolio. There is no public indication that a current third-party license creates a material patent royalty burden or restricts Kenvue’s ability to develop Pepcid line extensions.
How does Pepcid compare with proton-pump inhibitors?
| Attribute |
Pepcid, famotidine |
OTC proton-pump inhibitors |
| Onset |
Generally faster |
Slower for immediate relief |
| Duration |
Moderate |
Longer acid suppression |
| Best consumer fit |
Intermittent heartburn |
Frequent heartburn |
| Brand vulnerability |
High generic substitution |
Also high, but stronger chronic-use positioning |
| Product innovation |
Combination and strength extensions |
Regimens, packs, and long-duration claims |
| Patent position |
Expired |
Mostly mature and genericized |
| Main commercial advantage |
Familiar H2 blocker with rapid action |
Stronger positioning for recurring symptoms |
The categories are complementary rather than fully interchangeable. Pepcid is positioned for consumers who want relief before or after symptoms occur. Proton-pump inhibitors target consumers with more frequent symptoms and a willingness to use a multiday regimen.
What is the likely generic launch scenario for Pepcid?
Generic launch has already occurred. The forward-looking scenario is continued substitution, not a single future generic-entry event.
The likely commercial path is:
- Basic famotidine tablets remain heavily commoditized.
- Pepcid retains a branded premium in OTC retail.
- Combination products support higher price points.
- Private-label share increases during periods of consumer price sensitivity.
- Kenvue concentrates on distribution, advertising, and portfolio bundling.
- International outcomes vary according to local OTC rules, reimbursement, and brand ownership.
Geographic coverage is strongest where Pepcid has established consumer-health distribution. In markets where famotidine is prescription-only or where local brands dominate, the U.S. OTC model is less transferable.
What revenue exposure does Pepcid create for Kenvue?
Pepcid contributes to Kenvue’s Self Care segment but does not represent a separately disclosed concentration risk. The lack of standalone reporting means investors cannot directly observe Pepcid’s revenue, margin, or volume trends from Kenvue’s filings.
Its value is likely greater at the portfolio level than as an isolated growth engine. Pepcid adds a recognizable digestive-health brand to a portfolio that can share retail relationships, advertising capabilities, regulatory infrastructure, and international distribution.
The brand’s upside is limited by market maturity. Its downside is moderated by low research-and-development requirements and broad consumer awareness.
Key Takeaways
- Pepcid is an OTC famotidine brand marketed principally by Kenvue.
- Famotidine’s core patents expired decades ago; patent protection does not restrict generic entry.
- Pepcid’s principal defenses are trademark, brand recognition, retail access, and product extensions.
- The brand benefited materially from ranitidine’s 2020 withdrawal.
- Future growth is likely to be modest and driven by pricing, distribution, combination products, and share retention.
- Generic famotidine and private-label products are the primary competitive threats.
- Kenvue does not disclose Pepcid revenue separately, preventing a precise brand-level financial forecast.
- Orange Book and Paragraph IV issues are not major drivers of current Pepcid economics.
- The franchise has weak patent strength but durable commercial value as a mature OTC asset.
FAQs
Does Pepcid still have patent protection?
The foundational famotidine patents expired. Current Pepcid protection is primarily trademark, trade dress, regulatory compliance, and product-specific formulation rights.
Is Pepcid more profitable than generic famotidine?
Pepcid can generate higher gross profit per unit because of branded pricing, but generic famotidine has lower marketing and promotional costs. Relative profitability depends on channel discounts, manufacturing costs, and retailer terms.
Did ranitidine’s withdrawal permanently increase Pepcid sales?
It increased Pepcid demand sharply during the substitution period. The long-term increase is likely smaller because some consumers later returned to proton-pump inhibitors, antacids, or private-label products.
Can a company launch an OTC famotidine product without a Pepcid license?
Yes. A competitor can market famotidine if its product complies with FDA requirements and does not use Kenvue’s protected trademarks, packaging, or confusingly similar branding.
Is Pepcid exposed to biosimilar competition?
No. Famotidine is a chemically synthesized small molecule, not a biologic. Its competitive exposure comes from generic drugs and private-label OTC products, not biosimilars.
References
-
Food and Drug Administration. (2020, April 1). FDA requests removal of all ranitidine products from the market. U.S. Department of Health and Human Services. https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-market
-
Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
Kenvue Inc. (2024a). 2023 annual report. U.S. Securities and Exchange Commission.
-
Kenvue Inc. (2024b). Form 10-Q and quarterly financial disclosures. U.S. Securities and Exchange Commission.
-
U.S. Patent No. 4,496,737. (1985). 2-Guanidinothiazole derivatives. United States Patent and Trademark Office.
